Leerink Swann Starts Edwards Lifesciences (EW) at Outperform; Long-Term Growth Story Remains Compelling
Tweet
Share
E-mailGet Alerts EW Hot Sheet
Price: $91.60 -1.04%
Rating Summary:
31 Buy, 14 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
31 Buy, 14 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Leerink Swann initiates coverage on Edwards Lifesciences (NYSE: EW) with an Outperform. PT $90.00.
Leerink analyst says, "With the launch of its Sapien Transcatheter Heart Valve (THV) - the first transcatheter (delivered without open-heart surgery) valve to reach the US market - we believe EW is entering a multi-year period of significant, above industry growth and profitability expansion. For 2012-2015, we currently project ~11% sales and ~20% EPS CAGRs. Sapien's US uptake should also drive significant gross and operating margin expansion. We believe EW is among the most compelling growth and profitability expansion stories in large-cap MedTech. And we think there could be upside to our projections, depending on the speed of Sapien's and TAVR market uptake. Though challenges remain, over the next few years, we think EW shares should outperform peers as the company drives US Sapien adoption, the worldwide Transcatheter Aortic Valve Replacement (TAVR) market continues to develop, and EW realizes its significant profitability expansion potential."
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $77.68 yesterday.
Leerink analyst says, "With the launch of its Sapien Transcatheter Heart Valve (THV) - the first transcatheter (delivered without open-heart surgery) valve to reach the US market - we believe EW is entering a multi-year period of significant, above industry growth and profitability expansion. For 2012-2015, we currently project ~11% sales and ~20% EPS CAGRs. Sapien's US uptake should also drive significant gross and operating margin expansion. We believe EW is among the most compelling growth and profitability expansion stories in large-cap MedTech. And we think there could be upside to our projections, depending on the speed of Sapien's and TAVR market uptake. Though challenges remain, over the next few years, we think EW shares should outperform peers as the company drives US Sapien adoption, the worldwide Transcatheter Aortic Valve Replacement (TAVR) market continues to develop, and EW realizes its significant profitability expansion potential."
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $77.68 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- Evercore ISI Starts Alvotech SA (ALVO) at Outperform
- BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
